TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

80 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

    Testing whether empagliflozin is safe and helps children with chronic kidney disease

    📍 University of Alabama at Birmingham · Birmingham, AL · +29 more US sites · Get directions →

    This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Multiple sclerosis (MS)

    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus

    📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →

    The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

    ✓ Study care freePhase 3Ages 40–70Learn more →
  • Anxiety

    Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

    Testing a single oral dose medicine versus placebo for social anxiety in adults

    📍 Vanda Investigational Site · Phoenix, AZ · +30 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    Testing a modified ublituximab treatment for relapsing multiple sclerosis

    📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →

    The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

    Testing safety of a twice-yearly medicine for early relapsing MS

    📍 Northwestern Memorial Hospital · Chicago, IL · Get directions →

    In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Lupus (SLE)

    Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial

    Testing whether adding two lupus medicines to standard care improves kidney results

    📍 AARA Clinical Research · Glendale, AZ · +6 more US sites · Get directions →

    This is a Phase IV, open-label, randomized trial to determine whether the combination of Belimumab (BEL) and Voclosporin (VCS), plus background therapy with Mycophenolate Mofetil (MMF), improves the proportion of patients with proliferative lupus nephritis achieving complete renal response (CRR) compared to proportion of patients achieving CRR from recent clinical trials. This protocol will additionally determine whether combination therapy using Belimumab (BEL) and Voclosporin (VCS) facilitates rapid discontinuation of MMF.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Anxiety

    Self-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy

    Testing whether self-controlled nitrous oxide during vasectomy lowers pain and anxiety

    📍 Beth Israel Deaconess Medical Center · Boston, MA · Get directions →

    This study is being done to see if nitrous oxide during vasectomy decreases pain and anxiety, and also assess whether patients have better satisfaction when they control their own level of nitrous oxide during the procedure. If we find that patients experience less pain or anxiety with nitrous oxide, it could be suggested that self-adjusted nitrous oxide (SANO) may be a useful tool for improving experience of care during vasectomy.

    ✓ Study care freePhase 4Ages 21–85MenLearn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • Kidney disease

    CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

    Comparing how two beta-blockers work in hemodialysis patients on heart outcomes

    📍 VA Long Beach Healthcare System, Long Beach, CA · Long Beach, CA · +7 more US sites · Get directions →

    The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Multiple sclerosis (MS)

    Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis

    Testing whether combining a walking medication with physical therapy improves mobility in people

    📍 MGH Institute of Health Professions · Boston, MA · Get directions →

    The goal of this clinical trial is to evaluate if combining a medication that can help improve walking in people with multiple sclerosis (MS) with a physical therapy program is better for improving walking than either treatment alone. The main questions this study will answer are: * Does combining dalfampridine with physical therapy improve mobility more than physical therapy without concurrent dalfampridine?

    ✓ Study care freePhase 4Ages 25–75Learn more →
  • Lupus (SLE)

    Dapagliflozin in Active Lupus Nephritis

    Testing dapagliflozin for lupus-related kidney inflammation (kidney disease)

    📍 Massachusetts General Hospital · Boston, MA · +1 more US site · Get directions →

    Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Lupus (SLE)

    A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

    Testing enpatoran over 24 weeks for skin lupus symptoms, with or without whole-body disease

    📍 Inland Rheumatology Clinical Trials, Inc. · Upland, CA · +7 more US sites · Get directions →

    The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • DepressionAnxiety

    Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome

    Studying how gut bacteria in pregnant people relates to depression and anxiety

    📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →

    Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.

    ✓ Study care freePhase 2Ages 18–43WomenLearn more →
  • DepressionAnxiety

    Nebulized Ketamine for the Treatment of Major Depressive Disorder

    Testing a breathing mist of ketamine to reduce symptoms of major depression

    📍 Maimonides Medical Center · Brooklyn, NY · Get directions →

    This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

    ✓ Study care freePhase 3Ages 18–88Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    Testing a drug called orelabrutinib versus placebo in people with PPMS

    📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • DepressionAnxiety

    Creatine for Depressed Male and Female Methamphetamine Users

    Testing whether creatine helps depression and anxiety in people who use meth

    📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →

    * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

    ✓ Study care freePhase 3Ages 18–59Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis

    📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →

    This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.

    ✓ Study care freePhase 3Ages 18–55Learn more →
  • Lupus (SLE)

    Trial of Belimumab in Early Lupus

    Testing belimumab in people with lupus diagnosed within 2 years

    📍 Feinstein Institute · Manhasset, NY · Get directions →

    This two year study will evaluate the effects of giving belimumab (Benlysta) to patients with Early Lupus. Early lupus is a diagnosis of lupus within 2 years.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

    Testing etelcalcetide in children with kidney disease on dialysis

    📍 Childrens Hospital of Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →

    This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.

    ✓ Study care freePhase 3Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Lupus (SLE)

    📍 Pinnacle Research Group Llc · Anniston, AL · +20 more US sites · Get directions →

    The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

    ✓ Study care freePhase 3Ages 12–100Learn more →
  • Kidney disease

    Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial

    Testing medicines before surgery to reduce bleeding in kidney patients

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    The BRACKETS pilot study is a multicentre, prospective, randomized controlled trial of prophylactic preoperative tranexamic acid (TXA) versus placebo and, using a partial factorial design, of prophylactic preoperative desmopressin versus placebo.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Lupus (SLE)

    PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

    Testing LUPKYNIS with other lupus medicines for kidney response in lupus nephritis

    📍 Purushotham & Akther Kotha MD, Inc. · La Mesa, CA · +14 more US sites · Get directions →

    The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

    ✓ Study care freePhase 4Ages 18–75Learn more →
  • Kidney disease

    Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

    Testing long-term safety and effectiveness of zigakibart in adults with IgA kidney disease

    📍 Colorado Kidney Care Nephrology · Denver, CO · +6 more US sites · Get directions →

    The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

    ✓ Study care freePhase 3Ages 18–100Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple

    📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Anxiety

    Pharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE)

    Testing whether genetic-guided dosing of a daily anxiety medicine helps kids

    📍 University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience · Cincinnati, OH · Get directions →

    This double-blind, 12-week study will consist include132 anxious youth who are randomized (1:1) to standard or pharmacogenetically-guided escitalopram dosing. Block randomization (1:1) will be stratified by sex and metabolizer status.

    ✓ Study care freePhase 4Ages 12–17Learn more →
  • Lupus (SLE)

    Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

    Testing what happens to older people with lupus if they stop their hydroxychloroquine

    📍 University of California, Los Angeles · Los Angeles, CA · +9 more US sites · Get directions →

    Hydroxychloroquine (HCQ) is a systemic lupus erythematosus (SLE) medication that has been very effective in reducing lupus disease activity and keeping patients stable with reduced symptoms. Despite a track record of safety with regard to infection compared to traditional immunosuppressive agents, the risk of HCQ retinal toxicity escalates with continued use.

    ✓ Study care freePhase 3Ages 60+Learn more →
  • Anxiety

    Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study

    Testing whether adding L-methylfolate is safe and tolerated for hard-to-treat anxiety

    📍 Kingston Health Sciences Centre · Kingston, Ontario · Get directions →

    The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Home Based Infusions for Ocrelizumab

    Testing the safety and effectiveness of home infusions of ocrelizumab for multiple sclerosis

    📍 Amerita · Centennial, CO · Get directions →

    The goal is to assess the safety and effectiveness of home ocrelizumab infusion.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Multiple sclerosis (MS)

    📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →

    The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

    ✓ Study care freePhase 3Ages 10–17Learn more →
  • Anxiety

    📍 Servicios Especializados En Ensayos Clinicos, Seec, Sc · Mexico City, Mexico City · Get directions →

    To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the change in the GAD-7 scale at 12 weeks of treatment, relative to baseline.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Lupus (SLE)

    A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

    Testing the safety and effects of belimumab in early lupus adults

    📍 GSK Investigational Site · Anniston, AL · +39 more US sites · Get directions →

    This is a prospective, open-label, single arm 3-year clinical study to describe the short-term and long-term efficacy and safety of belimumab in participants with autoantibody positive early SLE with ongoing disease activity despite stable first-line SLE therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Lupus (SLE)

    A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

    Testing whether cenerimod added to usual treatment helps adults with active lupus nephritis

    💵 May compensate

    📍 Alloy Clinical Research LLC · Kissimmee, FL · +10 more US sites · Get directions →

    The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Kidney disease

    Bone in CKD Alkali Response (BICARb Pilot Trial)

    Testing whether potassium citrate improves bone health in people with chronic kidney disease

    📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →

    The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.

    ✓ Study care freePhase 2Ages 5–100Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis

    📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →

    The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • DepressionAnxiety

    Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)

    Testing a cognitive training program to see brain and thinking changes in people with depression or

    📍 UC San Diego · San Diego, CA · Get directions →

    The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.

    ✓ Study care freePhase 2Ages 21–55Learn more →
  • Kidney disease

    SAfety of Regional Citrate Anticoagulation (SARCA Study)

    Testing the safety of regional citrate blood-thinner use in adults

    📍 John L. McClellan Memorial Veterans' Hospital · Little Rock, AR · +9 more US sites · Get directions →

    This is an Open-label, Prospective, Multicenter Study to Assess the SAfety of Regional Citrate Anticoagulation Delivered by the multiFiltratePRO system in Adult Patients Requiring Continuous Renal Replacement Therapy (SARCA Study).

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Multiple sclerosis (MS)

    Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

    Testing whether ozanimod is safe and works as a step-down treatment for stable multiple sclerosis

    💵 May compensate

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · +2 more US sites · Get directions →

    A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

    Testing a treatment for adults with chronic kidney disease to help slow progression

    📍 Apogee Clinical Research · Huntsville, AL · +39 more US sites · Get directions →

    This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Kidney disease

    Patient-driven Management of BP in CKD

    Testing whether pharmacist-guided blood pressure management helps CKD patients lower blood pressure

    📍 Iowa City VA Health Care System, Iowa City, IA · Iowa City, IA · Get directions →

    The proposed research will evaluate if patients managing their blood pressure medications under the guidance of a clinical pharmacist works better to lower blood pressure than patients monitoring their blood pressure at home and the standard care. 60 Veterans with chronic kidney disease (CKD) will be included in the study.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Lupus (SLE)

    Safety of the Herpes Zoster Subunit Vaccine in Lupus

    Testing the safety of a shingles vaccine in people with lupus

    📍 NYU Langone Health · New York, NY · +1 more US site · Get directions →

    This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The investigators hypothesize that HZ/su administration will be non-inferior to placebo with respect to the risk of moderate or severe SLE flare(s) occurring within 24 weeks of receiving the first dose of the assigned treatment.

    ✓ Study care freePhase 4Ages 18–90Learn more →
  • Multiple sclerosis (MS)

    Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

    Testing whether switching from ocrelizumab to ublituximab helps MS symptoms that return

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.

    ✓ Study care freePhase 4Ages 18–65Learn more →
  • Lupus (SLE)

    A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

    Testing a treatment called enpatoran for skin lupus symptoms over 24 weeks

    📍 Dermatology Research Associates - 300204025 · Los Angeles, CA · +10 more US sites · Get directions →

    The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Lupus (SLE)

    An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

    Testing an IV medicine to study effects and safety in children with lupus

    📍 Research Site · Phoenix, AZ · +21 more US sites · Get directions →

    A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)

    ✓ Study care freePhase 3Ages 5–17Learn more →
  • Multiple sclerosis (MS)

    Glucose Consumption in MS Using [F-18]FDG-PET

    Testing how [F-18]FDG PET shows glucose use in people with MS and controls

    📍 Brigham & Women's Hospital · Boston, MA · Get directions →

    Given the need for better diagnostic imaging techniques in multiple sclerosis (MS), the study aims to investigate the utility of \[F-18\]FDG positron emission tomography (PET) in MS. The study will be assessing glucose consumption patterns in subjects with progressive MS (PMS) and relapsing-remitting MS (RRMS), as well as healthy controls.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Anxiety

    Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder

    Testing cannabidiol added to talk therapy for adults with generalized anxiety

    📍 Wayne State University School of Medicine, Tolan Park Medical Building · Detroit, MI · Get directions →

    This randomized, double-blind, placebo-controlled clinical trial investigates the use of Food and Drug Administration (FDA)-approved cannabidiol (EPIDIOLEX®) as an adjunct to cognitive behavioral therapy (CBT) in adults with generalized anxiety disorder (GAD). The study aims to evaluate whether cannabidiol-assisted CBT enhances emotion regulation via dorsomedial prefrontal cortex (dmPFC) activation and improves anxiety symptom outcomes compared to CBT with placebo.

    ✓ Study care freePhase 3Ages 18–45Learn more →
  • Multiple sclerosis (MS)

    Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

    Testing whether silodosin helps lower urinary tract symptoms in women with multiple sclerosis

    📍 Atlantic Health · Morristown, NJ · Get directions →

    The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.

    ✓ Study care freePhase 4Ages 18+WomenLearn more →
  • Multiple sclerosis (MS)

    ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS

    Testing eye-tracking measures to track disease changes in relapsing-remitting multiple sclerosis

    📍 Novartis Investigative Site · Calgary, Alberta · Get directions →

    The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context of disease-modifying treatment (i.e., ofatumumab). To that end, the study will use the patented investigational, Eye Tracking Neurological Assessment (ETNA-ProgMS) SaMD (v1.0.11 or later), which has not yet received Health Canada approval, to reliably and accurately track eye movements with precision.

    ✓ Study care freePhase 4Ages 18–99Learn more →
  • Kidney disease

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Testing whether a weekly diabetes medicine is safe for people on dialysis

    📍 Unity Health Toronto · Toronto, Ontario · Get directions →

    This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Studying weight-loss support for people with obesity and kidney disease who want a kidney transplant

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Lupus (SLE)

    Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

    Tracking how anifrolumab passes into breast milk and affects infants in people with lupus

    📍 Research Site · Las Vegas, NV · Get directions →

    Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users (PRIMULA Lac) is a Post Marketing Requirements (PMR) study designed to fulfill the FDA post-marketing requirements. The study will collect data about the presence of anifrolumab in human breast milk and serum (maternal and infant) among lactating individuals who are receiving anifrolumab therapeutically via intravenous (IV) or subcutaneous (SC) administration and evaluate exposure and effects on the breastfed infant.

    ✓ Study care freePhase 4Ages 18–130WomenLearn more →
  • Lupus (SLE)

    📍 Sl0044 50058 · Avondale, AZ · +39 more US sites · Get directions →

    The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.

    ✓ Study care freePhase 3Ages 16+Learn more →
  • Kidney disease

    📍 Memorial Healthcare System · Hollywood, FL · +7 more US sites · Get directions →

    Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

    ✓ Study care freePhase 3Ages 2–17Learn more →
  • Kidney disease

    Shingrix in Renal Transplant Recipients

    Testing how well and how safely the shingles vaccine works in people with kidney failure before and

    📍 University of Colorado Anschutz · Aurora, CO · +3 more US sites · Get directions →

    The goal of this clinical trial is to learn how well the shingles vaccine (Shingrix) works and how safe it is in adults with kidney failure who are waiting for a kidney transplant, including those who later receive a transplant. The study also aims to find out whether giving an extra (third) dose of the vaccine after transplant improves protection.

    ✓ Study care freePhase 3Ages 18–70Learn more →
  • Kidney disease

    A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

    Testing an iron-based phosphate binder to lower blood phosphate in dialysis patients

    📍 Renal Consultants Medical Group · Granada Hills, CA · +18 more US sites · Get directions →

    The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels?

    ✓ Study care freePhase 3Ages 12+Learn more →
  • Multiple sclerosis (MS)

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

    Testing stopping ocrelizumab in people with relapsing multiple sclerosis

    📍 Yale School of Medicine · New Haven, CT · +12 more US sites · Get directions →

    This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with early RMS. All eligible participants will be initiated on OCR using the standard approved administration schedule of two 300 mg infusions separated by 14 days (i.e., Days 0 and 14) for a total of 600 mg, followed by 600 mg infusions at Month 6,12, 18, and 24.

    ✓ Study care freePhase 4Ages 18–55Learn more →
  • Showing the first 60 of 80. Add filters or a location to narrow down.